Srikanth Vallurupalli
Concepts (292)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Coronary Artery Disease | 12 | 2024 | 272 | 4.540 |
Why?
| Atrial Fibrillation | 5 | 2022 | 182 | 2.520 |
Why?
| Percutaneous Coronary Intervention | 9 | 2022 | 298 | 2.450 |
Why?
| Ventricular Dysfunction, Right | 3 | 2023 | 31 | 2.360 |
Why?
| Aortic Valve Stenosis | 5 | 2021 | 60 | 2.220 |
Why?
| Ventricular Function, Right | 5 | 2023 | 39 | 2.130 |
Why?
| Stents | 8 | 2022 | 346 | 2.070 |
Why?
| Echocardiography | 12 | 2024 | 382 | 2.040 |
Why?
| Angioplasty, Balloon, Coronary | 4 | 2018 | 137 | 2.030 |
Why?
| Myocardial Infarction | 5 | 2024 | 391 | 1.920 |
Why?
| Endocarditis | 2 | 2022 | 31 | 1.380 |
Why?
| Echocardiography, Doppler | 2 | 2022 | 52 | 1.360 |
Why?
| Aortic Valve | 3 | 2020 | 109 | 1.350 |
Why?
| Thrombocytopenia | 2 | 2022 | 79 | 1.340 |
Why?
| Treatment Outcome | 26 | 2022 | 5178 | 1.300 |
Why?
| Electrocardiography | 6 | 2024 | 259 | 1.260 |
Why?
| Humans | 69 | 2024 | 49929 | 1.250 |
Why?
| Fractional Flow Reserve, Myocardial | 4 | 2022 | 126 | 1.160 |
Why?
| Heart Failure | 6 | 2022 | 505 | 1.130 |
Why?
| Ischemic Attack, Transient | 2 | 2018 | 56 | 1.100 |
Why?
| Veterans | 2 | 2022 | 564 | 0.990 |
Why?
| Heart Ventricles | 5 | 2022 | 252 | 0.990 |
Why?
| Stroke | 3 | 2021 | 478 | 0.970 |
Why?
| Exercise Test | 3 | 2024 | 129 | 0.890 |
Why?
| Coronary Stenosis | 2 | 2021 | 99 | 0.870 |
Why?
| Coronary Angiography | 9 | 2022 | 353 | 0.850 |
Why?
| Risk Factors | 16 | 2022 | 3605 | 0.850 |
Why?
| Thrombosis | 3 | 2024 | 249 | 0.810 |
Why?
| Electric Countershock | 1 | 2022 | 30 | 0.790 |
Why?
| Endocarditis, Bacterial | 1 | 2022 | 44 | 0.790 |
Why?
| Atrial Appendage | 1 | 2021 | 11 | 0.780 |
Why?
| Kidney Diseases | 3 | 2021 | 211 | 0.780 |
Why?
| Anemia | 1 | 2022 | 66 | 0.770 |
Why?
| Retrospective Studies | 16 | 2023 | 6124 | 0.760 |
Why?
| Catheter Ablation | 2 | 2021 | 122 | 0.750 |
Why?
| Pulmonary Artery | 1 | 2022 | 145 | 0.750 |
Why?
| Anticholesteremic Agents | 1 | 2021 | 28 | 0.750 |
Why?
| Hypercholesterolemia | 1 | 2021 | 36 | 0.740 |
Why?
| Cryosurgery | 1 | 2021 | 35 | 0.720 |
Why?
| Systole | 4 | 2023 | 71 | 0.710 |
Why?
| Magnetic Resonance Imaging, Cine | 3 | 2016 | 59 | 0.700 |
Why?
| Operative Time | 2 | 2017 | 71 | 0.690 |
Why?
| Male | 32 | 2024 | 25454 | 0.690 |
Why?
| Dyspnea | 3 | 2018 | 74 | 0.680 |
Why?
| Heart | 2 | 2021 | 336 | 0.680 |
Why?
| Predictive Value of Tests | 10 | 2022 | 907 | 0.670 |
Why?
| Digitalis | 1 | 2019 | 5 | 0.670 |
Why?
| Anticoagulants | 3 | 2022 | 254 | 0.670 |
Why?
| Aged | 20 | 2022 | 9449 | 0.650 |
Why?
| Cardiac Catheters | 1 | 2018 | 12 | 0.610 |
Why?
| Auscultation | 1 | 2018 | 9 | 0.610 |
Why?
| Middle Aged | 22 | 2024 | 12293 | 0.610 |
Why?
| Heart Murmurs | 1 | 2018 | 13 | 0.610 |
Why?
| Asymptomatic Diseases | 1 | 2018 | 36 | 0.600 |
Why?
| Female | 28 | 2022 | 26576 | 0.600 |
Why?
| Time Factors | 9 | 2022 | 2891 | 0.580 |
Why?
| Drug Prescriptions | 1 | 2018 | 95 | 0.580 |
Why?
| Heart Diseases | 2 | 2017 | 211 | 0.580 |
Why?
| Coronary Disease | 2 | 2015 | 152 | 0.570 |
Why?
| Artifacts | 1 | 2017 | 53 | 0.570 |
Why?
| Peripheral Arterial Disease | 1 | 2018 | 67 | 0.570 |
Why?
| Mediastinal Neoplasms | 1 | 2017 | 19 | 0.550 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 137 | 0.550 |
Why?
| Hospital Mortality | 2 | 2018 | 409 | 0.550 |
Why?
| Coronary Occlusion | 1 | 2017 | 78 | 0.540 |
Why?
| Surgical Procedures, Operative | 1 | 2017 | 66 | 0.530 |
Why?
| Absorbable Implants | 1 | 2016 | 16 | 0.530 |
Why?
| Tomography, Optical Coherence | 1 | 2017 | 104 | 0.530 |
Why?
| Acute Coronary Syndrome | 1 | 2017 | 78 | 0.520 |
Why?
| Pneumonia | 1 | 2017 | 117 | 0.520 |
Why?
| Respiratory Insufficiency | 1 | 2017 | 115 | 0.510 |
Why?
| Propafenone | 1 | 2015 | 2 | 0.510 |
Why?
| Tachycardia, Ectopic Atrial | 1 | 2015 | 3 | 0.510 |
Why?
| Flecainide | 1 | 2015 | 5 | 0.510 |
Why?
| Heart Conduction System | 1 | 2015 | 23 | 0.500 |
Why?
| Prognosis | 6 | 2024 | 1957 | 0.500 |
Why?
| Hypoparathyroidism | 1 | 2015 | 5 | 0.500 |
Why?
| Hypocalcemia | 1 | 2015 | 12 | 0.490 |
Why?
| Heart Rate | 2 | 2021 | 299 | 0.490 |
Why?
| Rhabdomyolysis | 1 | 2015 | 12 | 0.490 |
Why?
| Clinical Competence | 1 | 2018 | 396 | 0.480 |
Why?
| Cardiac Surgical Procedures | 2 | 2017 | 304 | 0.470 |
Why?
| Thyroidectomy | 1 | 2015 | 59 | 0.470 |
Why?
| Physician-Patient Relations | 1 | 2015 | 143 | 0.450 |
Why?
| Fibroma | 1 | 2014 | 39 | 0.450 |
Why?
| Heart Neoplasms | 1 | 2014 | 32 | 0.450 |
Why?
| Ventricular Function, Left | 4 | 2019 | 158 | 0.450 |
Why?
| Recurrence | 4 | 2021 | 658 | 0.440 |
Why?
| Theophylline | 1 | 2013 | 21 | 0.440 |
Why?
| Syncope | 1 | 2013 | 28 | 0.420 |
Why?
| Diabetes Mellitus, Type 2 | 4 | 2022 | 483 | 0.420 |
Why?
| Physicians | 1 | 2015 | 229 | 0.390 |
Why?
| Heart Valve Prosthesis | 2 | 2022 | 78 | 0.380 |
Why?
| Heart Valve Prosthesis Implantation | 2 | 2022 | 80 | 0.380 |
Why?
| Amyloidosis | 3 | 2016 | 77 | 0.360 |
Why?
| Sulfonylurea Compounds | 1 | 2010 | 2 | 0.350 |
Why?
| Octreotide | 1 | 2010 | 9 | 0.350 |
Why?
| Arkansas | 6 | 2019 | 1990 | 0.350 |
Why?
| Ventricular Remodeling | 3 | 2021 | 53 | 0.340 |
Why?
| Benzocaine | 1 | 2009 | 4 | 0.340 |
Why?
| Head and Neck Neoplasms | 1 | 2013 | 281 | 0.340 |
Why?
| Methemoglobinemia | 1 | 2009 | 6 | 0.340 |
Why?
| Hypoglycemia | 1 | 2010 | 52 | 0.330 |
Why?
| Echocardiography, Transesophageal | 1 | 2009 | 60 | 0.320 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1037 | 0.320 |
Why?
| Anesthetics, Local | 1 | 2009 | 74 | 0.320 |
Why?
| Stroke Volume | 2 | 2019 | 130 | 0.310 |
Why?
| Prospective Studies | 3 | 2023 | 2345 | 0.300 |
Why?
| Prosthesis Design | 3 | 2022 | 240 | 0.300 |
Why?
| Vasodilator Agents | 2 | 2022 | 98 | 0.300 |
Why?
| Incidence | 5 | 2019 | 986 | 0.290 |
Why?
| Myocardial Contraction | 2 | 2019 | 110 | 0.290 |
Why?
| Coronary Vessels | 2 | 2020 | 158 | 0.280 |
Why?
| Chronic Disease | 3 | 2018 | 566 | 0.270 |
Why?
| Pressure | 2 | 2017 | 105 | 0.270 |
Why?
| Defibrillators, Implantable | 2 | 2019 | 63 | 0.260 |
Why?
| Reproducibility of Results | 2 | 2021 | 1182 | 0.250 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2022 | 550 | 0.250 |
Why?
| Follow-Up Studies | 5 | 2019 | 2177 | 0.240 |
Why?
| Cardiomyopathies | 2 | 2016 | 114 | 0.240 |
Why?
| Cardiac Catheterization | 3 | 2022 | 214 | 0.240 |
Why?
| Foramen Ovale, Patent | 2 | 2015 | 27 | 0.240 |
Why?
| Myxoma | 1 | 2024 | 16 | 0.230 |
Why?
| Hepatitis C, Chronic | 2 | 2015 | 86 | 0.230 |
Why?
| Hospitalization | 4 | 2022 | 663 | 0.210 |
Why?
| Risk Assessment | 4 | 2022 | 1255 | 0.210 |
Why?
| Mitral Valve Insufficiency | 1 | 2022 | 45 | 0.200 |
Why?
| Bioprosthesis | 1 | 2022 | 37 | 0.200 |
Why?
| Proportional Hazards Models | 3 | 2020 | 404 | 0.200 |
Why?
| Electrodes | 1 | 2022 | 35 | 0.200 |
Why?
| Adult | 8 | 2018 | 13356 | 0.200 |
Why?
| Warfarin | 1 | 2022 | 83 | 0.190 |
Why?
| Pilot Projects | 2 | 2022 | 702 | 0.190 |
Why?
| Multiple Myeloma | 4 | 2017 | 2916 | 0.190 |
Why?
| Severity of Illness Index | 2 | 2018 | 953 | 0.190 |
Why?
| Sodium-Glucose Transporter 1 | 1 | 2020 | 5 | 0.190 |
Why?
| Glycosides | 1 | 2020 | 18 | 0.190 |
Why?
| Microscopy, Fluorescence, Multiphoton | 1 | 2020 | 6 | 0.180 |
Why?
| Vasodilation | 1 | 2021 | 97 | 0.180 |
Why?
| Tachycardia, Supraventricular | 1 | 2021 | 39 | 0.180 |
Why?
| United States | 3 | 2022 | 4883 | 0.180 |
Why?
| Cardiovascular System | 1 | 2020 | 50 | 0.180 |
Why?
| Calcinosis | 1 | 2020 | 52 | 0.180 |
Why?
| United States Department of Veterans Affairs | 1 | 2022 | 287 | 0.180 |
Why?
| Blood Pressure | 1 | 2022 | 519 | 0.170 |
Why?
| Digoxin | 1 | 2019 | 30 | 0.170 |
Why?
| Heart Failure, Systolic | 1 | 2019 | 7 | 0.170 |
Why?
| Electric Stimulation Therapy | 1 | 2019 | 23 | 0.160 |
Why?
| Inpatients | 2 | 2018 | 193 | 0.160 |
Why?
| Metoprolol | 1 | 2019 | 13 | 0.160 |
Why?
| Cardiotonic Agents | 1 | 2019 | 82 | 0.160 |
Why?
| Platelet Transfusion | 1 | 2018 | 28 | 0.160 |
Why?
| Kaplan-Meier Estimate | 2 | 2017 | 463 | 0.160 |
Why?
| Cerebrovascular Disorders | 1 | 2018 | 48 | 0.150 |
Why?
| Hepatitis C Antibodies | 2 | 2015 | 20 | 0.150 |
Why?
| Delivery of Health Care | 1 | 2021 | 308 | 0.150 |
Why?
| Databases, Factual | 2 | 2018 | 660 | 0.150 |
Why?
| Cardiovascular Diseases | 3 | 2020 | 445 | 0.150 |
Why?
| Renal Insufficiency, Chronic | 1 | 2020 | 170 | 0.150 |
Why?
| Cardiac Imaging Techniques | 1 | 2017 | 8 | 0.140 |
Why?
| Fever | 1 | 2018 | 111 | 0.140 |
Why?
| Logistic Models | 2 | 2017 | 896 | 0.140 |
Why?
| Cell Transdifferentiation | 1 | 2017 | 8 | 0.140 |
Why?
| Xanthine Oxidase | 1 | 2017 | 14 | 0.140 |
Why?
| Hepacivirus | 2 | 2015 | 105 | 0.140 |
Why?
| Foam Cells | 1 | 2017 | 16 | 0.140 |
Why?
| Cohort Studies | 2 | 2018 | 1403 | 0.140 |
Why?
| Hemorrhage | 1 | 2018 | 194 | 0.140 |
Why?
| Survival Rate | 2 | 2019 | 905 | 0.140 |
Why?
| Respiratory Sounds | 1 | 2017 | 48 | 0.140 |
Why?
| Myocytes, Smooth Muscle | 1 | 2017 | 85 | 0.140 |
Why?
| Radiographic Image Enhancement | 1 | 2016 | 30 | 0.130 |
Why?
| Propensity Score | 1 | 2017 | 125 | 0.130 |
Why?
| Gadolinium DTPA | 1 | 2016 | 25 | 0.130 |
Why?
| Chi-Square Distribution | 1 | 2017 | 275 | 0.130 |
Why?
| Kidney | 1 | 2020 | 672 | 0.130 |
Why?
| Inflammasomes | 1 | 2017 | 62 | 0.130 |
Why?
| Muscle, Smooth, Vascular | 1 | 2017 | 131 | 0.130 |
Why?
| Quality Improvement | 1 | 2018 | 205 | 0.130 |
Why?
| Magnetic Resonance Imaging | 3 | 2024 | 1526 | 0.130 |
Why?
| Voltage-Gated Sodium Channel Blockers | 1 | 2015 | 5 | 0.130 |
Why?
| Intermittent Claudication | 1 | 2015 | 12 | 0.130 |
Why?
| Ventricular Function | 1 | 2015 | 19 | 0.130 |
Why?
| Fundoplication | 1 | 2015 | 19 | 0.130 |
Why?
| Goiter | 1 | 2015 | 4 | 0.120 |
Why?
| Healthcare Disparities | 1 | 2018 | 282 | 0.120 |
Why?
| Postpericardiotomy Syndrome | 1 | 2015 | 4 | 0.120 |
Why?
| Immobilization | 1 | 2015 | 14 | 0.120 |
Why?
| Supine Position | 1 | 2015 | 28 | 0.120 |
Why?
| Pericardiectomy | 1 | 2015 | 6 | 0.120 |
Why?
| Aged, 80 and over | 3 | 2018 | 3138 | 0.120 |
Why?
| Length of Stay | 1 | 2018 | 624 | 0.120 |
Why?
| Colchicine | 1 | 2015 | 24 | 0.120 |
Why?
| Pericarditis | 1 | 2015 | 21 | 0.120 |
Why?
| Mucolipidoses | 1 | 2014 | 4 | 0.120 |
Why?
| Secondary Prevention | 1 | 2015 | 78 | 0.120 |
Why?
| Scavenger Receptors, Class E | 1 | 2017 | 203 | 0.120 |
Why?
| Carcinoma, Renal Cell | 1 | 2015 | 101 | 0.120 |
Why?
| Obesity, Morbid | 1 | 2015 | 74 | 0.110 |
Why?
| Sulfonamides | 1 | 2015 | 125 | 0.110 |
Why?
| Thoracotomy | 1 | 2014 | 35 | 0.110 |
Why?
| Septal Occluder Device | 1 | 2014 | 30 | 0.110 |
Why?
| Pyrimidines | 1 | 2015 | 192 | 0.110 |
Why?
| Kidney Neoplasms | 1 | 2015 | 172 | 0.110 |
Why?
| Bone Marrow Transplantation | 1 | 2014 | 112 | 0.110 |
Why?
| Laparoscopy | 1 | 2015 | 170 | 0.110 |
Why?
| Mitral Valve | 2 | 2022 | 50 | 0.100 |
Why?
| Prosthesis Failure | 2 | 2022 | 108 | 0.100 |
Why?
| Administration, Oral | 1 | 2013 | 433 | 0.100 |
Why?
| Tomography, X-Ray Computed | 1 | 2017 | 1153 | 0.090 |
Why?
| Postoperative Complications | 2 | 2015 | 1018 | 0.090 |
Why?
| Injections, Subcutaneous | 1 | 2010 | 51 | 0.090 |
Why?
| Pericardium | 1 | 2010 | 28 | 0.090 |
Why?
| Gastrointestinal Agents | 1 | 2010 | 35 | 0.080 |
Why?
| Drug Monitoring | 1 | 2010 | 78 | 0.080 |
Why?
| Quality of Life | 1 | 2015 | 838 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 994 | 0.080 |
Why?
| Cause of Death | 2 | 2020 | 147 | 0.080 |
Why?
| Lipid Metabolism | 1 | 2010 | 175 | 0.080 |
Why?
| Renal Dialysis | 1 | 2010 | 170 | 0.080 |
Why?
| Kidney Failure, Chronic | 1 | 2010 | 198 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 1 | 2010 | 1354 | 0.070 |
Why?
| Exercise | 1 | 2010 | 493 | 0.060 |
Why?
| Oxidative Stress | 1 | 2010 | 759 | 0.060 |
Why?
| Disease Progression | 2 | 2020 | 820 | 0.060 |
Why?
| RNA, Viral | 2 | 2015 | 124 | 0.060 |
Why?
| Heart Atria | 1 | 2024 | 58 | 0.060 |
Why?
| Gadolinium | 1 | 2024 | 42 | 0.060 |
Why?
| Vitamin K | 1 | 2022 | 16 | 0.050 |
Why?
| Contrast Media | 1 | 2024 | 186 | 0.050 |
Why?
| American Heart Association | 1 | 2022 | 32 | 0.050 |
Why?
| Telemetry | 1 | 2021 | 29 | 0.050 |
Why?
| Tachycardia | 1 | 2021 | 29 | 0.050 |
Why?
| Glucosides | 1 | 2020 | 13 | 0.050 |
Why?
| Acute Disease | 1 | 2022 | 367 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2022 | 174 | 0.050 |
Why?
| Diabetic Ketoacidosis | 1 | 2020 | 17 | 0.050 |
Why?
| Glomerular Filtration Rate | 1 | 2020 | 110 | 0.050 |
Why?
| Early Diagnosis | 1 | 2020 | 87 | 0.040 |
Why?
| Benzhydryl Compounds | 1 | 2020 | 66 | 0.040 |
Why?
| Exercise Tolerance | 1 | 2019 | 40 | 0.040 |
Why?
| Death, Sudden, Cardiac | 1 | 2019 | 57 | 0.040 |
Why?
| Anti-Arrhythmia Agents | 1 | 2019 | 81 | 0.040 |
Why?
| Recovery of Function | 1 | 2019 | 187 | 0.040 |
Why?
| Oxygen Consumption | 1 | 2019 | 188 | 0.040 |
Why?
| Adrenergic beta-Antagonists | 1 | 2019 | 106 | 0.040 |
Why?
| Feasibility Studies | 1 | 2020 | 382 | 0.040 |
Why?
| Uric Acid | 1 | 2017 | 21 | 0.040 |
Why?
| Registries | 1 | 2020 | 523 | 0.030 |
Why?
| Scavenger Receptors, Class A | 1 | 2017 | 39 | 0.030 |
Why?
| Referral and Consultation | 1 | 2018 | 285 | 0.030 |
Why?
| RNA Interference | 1 | 2017 | 178 | 0.030 |
Why?
| Transfection | 1 | 2017 | 354 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2016 | 182 | 0.030 |
Why?
| ROC Curve | 1 | 2016 | 225 | 0.030 |
Why?
| Hernia, Hiatal | 1 | 2015 | 9 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2020 | 1411 | 0.030 |
Why?
| Patient Acceptance of Health Care | 1 | 2018 | 338 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2020 | 1777 | 0.030 |
Why?
| Gastroesophageal Reflux | 1 | 2015 | 50 | 0.030 |
Why?
| Tubulin Modulators | 1 | 2015 | 27 | 0.030 |
Why?
| Indazoles | 1 | 2015 | 44 | 0.030 |
Why?
| Reactive Oxygen Species | 1 | 2017 | 405 | 0.030 |
Why?
| Seroepidemiologic Studies | 1 | 2014 | 51 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2016 | 579 | 0.030 |
Why?
| Biopsy | 1 | 2016 | 591 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 670 | 0.030 |
Why?
| Pneumonectomy | 1 | 2014 | 31 | 0.030 |
Why?
| Posture | 1 | 2014 | 60 | 0.030 |
Why?
| Angiogenesis Inhibitors | 1 | 2015 | 182 | 0.030 |
Why?
| Prosthesis Implantation | 1 | 2014 | 46 | 0.030 |
Why?
| Myocardium | 1 | 2016 | 443 | 0.030 |
Why?
| Anti-Inflammatory Agents | 1 | 2015 | 160 | 0.030 |
Why?
| Syndrome | 1 | 2014 | 237 | 0.030 |
Why?
| Age Distribution | 1 | 2013 | 169 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2014 | 456 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2016 | 972 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2014 | 101 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2017 | 1388 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2014 | 462 | 0.020 |
Why?
| Comorbidity | 1 | 2013 | 610 | 0.020 |
Why?
| Oxygen | 1 | 2014 | 323 | 0.020 |
Why?
| alpha-2-HS-Glycoprotein | 1 | 2010 | 1 | 0.020 |
Why?
| Thiobarbituric Acid Reactive Substances | 1 | 2010 | 10 | 0.020 |
Why?
| Signal Transduction | 1 | 2017 | 1608 | 0.020 |
Why?
| Blood Proteins | 1 | 2010 | 77 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2010 | 143 | 0.020 |
Why?
| Interleukin-6 | 1 | 2010 | 265 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2014 | 602 | 0.020 |
Why?
| Animals | 1 | 2020 | 13100 | 0.020 |
Why?
| Young Adult | 1 | 2013 | 4031 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 6417 | 0.010 |
Why?
|
|
Vallurupalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|